TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 3, 2010, Pages 445-453

  Vanhoutte, Davy ^a,b   Heymans, Stephane ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Angiogenesis; Cardiac remodeling; Cardiomyocytes; Endothelial cell; Fibroblast; Heart failure; Inflammation; Matrix metalloproteinases (MMPs); Receptor signaling; Review; Therapy; Tissue inhibitors of matrix metalloproteinase (TIMP)

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BATIMASTAT; COLLAGENASE 3; CP 471474; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR INFLAMMATION; CELL BASED GENE THERAPY; CELL PROLIFERATION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE REPAIR;

ANIMALS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 77649273607     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.09.013     Document Type: Review

References (62)

1. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87:1285-1342.
2. Vanhoutte D., Schellings M., Pinto Y., Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 2006, 69:604-613.
3. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 2006, 69:614-624.
4. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123:255-278.
5. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
6. Yu W.H., Yu S., Meng Q., Brew K., Woessner J.F. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 2000, 275:31226-31232.
7. Matsumura S., Iwanaga S., Mochizuki S., Okamoto H., Ogawa S., Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest. 2005, 115:599-609.
8. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 1999, 5:1135-1142.
9. Lindsey M.L., Escobar G.P., Dobrucki L.W., Goshorn D.K., Bouges S., Mingoia J.T., et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol., Heart Circ. Physiol. 2006, 290:H232-H239.
10. Lindsey M.L., Escobar G.P., Mukherjee R., Goshorn D.K., Sheats N.J., Bruce J.A., et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113:2919-2928.
11. Creemers E.E., Davis J.N., Parkhurst A.M., Leenders P., Dowdy K.B., Hapke E., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am. J. Physiol., Heart Circ. Physiol. 2003, 284:H364-H371.
12. Tian H., Cimini M., Fedak P.W., Altamentova S., Fazel S., Huang M.L., et al. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J. Mol. Cell. Cardiol. 2007, 43:733-743.
13. Cheung C., Marchant D., Walker E.K., Luo Z., Zhang J., Yanagawa B., et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008, 117:1574-1582.
14. Heymans S., Pauschinger M., De Palma A., Kallwellis-Opara A., Rutschow S., Swinnen M., et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006, 114:565-573.
15. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004, 110:2401-2409.
16. Kim H.E., Dalal S.S., Young E., Legato M.J., Weisfeldt M.L., D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J. Clin. Invest. 2000, 106:857-866.
17. Heymans S., Lupu F., Terclavers S., Vanwetswinkel B., Herbert J.M., Baker A., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am. J. Pathol. 2005, 166:15-25.
18. Heymans S., Schroen B., Vermeersch P., Milting H., Gao F., Kassner A., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005, 112:1136-1144.
19. Kassiri Z., Oudit G.Y., Sanchez O., Dawood F., Mohammed F.F., Nuttall R.K., et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ. Res. 2005, 97:380-390.
20. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
21. Lovelock J.D., Baker A.H., Gao F., Dong J.F., Bergeron A.L., McPheat W., et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am. J. Physiol., Heart Circ. Physiol. 2005, 288:H461-H468.
22. Heineke J., Auger-Messier M., Xu J., Oka T., Sargent M.A., York A., et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 2007, 117:3198-3210.
23. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
24. Murphy A.N., Unsworth E.J., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol. 1993, 157:351-358.
25. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002, 105:753-758.
26. Akahane T., Akahane M., Shah A., Connor C.M., Thorgeirsson U.P. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp. Cell Res. 2004, 301:158-167.
27. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 2003, 9:407-415.
28. Kang K.H., Park S.Y., Rho S.B., Lee J.H. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc. Res. 2008, 79:150-160.
29. Seo D.W., Li H., Guedez L., Wingfield P.T., Diaz T., Salloum R., et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114:171-180.
30. Oh J., Diaz T., Wei B., Chang H., Noda M., Stetler-Stevenson W.G. TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 2006, 25:4230-4234.
31. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev., Mol. Cell Biol. 2008, 9:690-701.
32. Bos J.L. Linking Rap to cell adhesion. Curr. Opin. Cell Biol. 2005, 17:123-128.
33. Oh J., Seo D.W., Diaz T., Wei B., Ward Y., Ray J.M., et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 2004, 64:9062-9069.
34. Seo D.W., Li H., Qu C.K., Oh J., Kim Y.S., Diaz T., et al. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J. Biol. Chem. 2006, 281:3711-3721.
35. Roncal C., Buysschaert I., Chorianopoulos E., Georgiadou M., Meilhac O., Demol M., et al. Beneficial effects of prolonged systemic administration of PlGF on late outcome of post-ischaemic myocardial performance. J. Pathol. 2008, 216:236-244.
36. Baker A.H., Zaltsman A.B., George S.J., Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. 1998, 101:1478-1487.
37. George S.J., Lloyd C.T., Angelini G.D., Newby A.C., Baker A.H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000, 101:296-304.
38. Pasumarthi K.B., Field L.J. Cardiomyocyte cell cycle regulation. Circ. Res. 2002, 90:1044-1054.
39. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev., Mol. Cell Biol. 2006, 7:589-600.
40. Hammoud L., Xiang F., Lu X., Brunner F., Leco K., Feng Q. Endothelial nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting tissue inhibitor of metalloproteinase-3 expression. Cardiovasc. Res. 2007, 75:359-368.
41. Hammoud L., Burger D.E., Lu X., Feng Q. Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling. Am. J. Physiol., Cell Physiol. 2009, 296:C735-C745.
42. Lin J., Davis H.B., Dai Q., Chou Y.M., Craig T., Hinojosa-Laborde C., et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens. Res. 2008, 31:1225-1231.
43. Mujumdar V.S., Tyagi S.C. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J. Hypertens. 1999, 17:261-270.
44. Wisniewska M., Goettig P., Maskos K., Belouski E., Winters D., Hecht R., et al. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J. Mol. Biol. 2008, 381:1307-1319.
45. Meier H., Bullinger J., Deten A., Marx G., Rabald S., Zimmer H.G., et al. Tissue inhibitor of matrix metalloproteinase-1 in norepinephrine-induced remodeling of the mouse heart. Cell. Physiol. Biochem. 2007, 20:825-836.
46. Bubikat A., De Windt L.J., Zetsche B., Fabritz L., Sickler H., Eckardt D., et al. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J. Biol. Chem. 2005, 280:21594-21599.
47. Senbonmatsu T., Saito T., Landon E.J., Watanabe O., Price E., Roberts R.L., et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 2003, 22:6471-6482.
48. Widdop R.E., Jones E.S., Hannan R.E., Gaspari T.A. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br. J. Pharmacol. 2003, 140:809-824.
49. Smookler D.S., Mohammed F.F., Kassiri Z., Duncan G.S., Mak T.W., Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 2006, 176:721-725.
50. Guedez L., Stetler-Stevenson W.G., Wolff L., Wang J., Fukushima P., Mansoor A., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest. 1998, 102:2002-2010.
51. Guedez L., Courtemanch L., Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92:1342-1349.
52. Kim Y.S., Seo D.W., Kong S.K., Lee J.H., Lee E.S., Stetler-Stevenson M., et al. TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation. Cancer Lett. 2008, 269:37-45.
53. Lim M.S., Guedez L., Stetler-Stevenson W.G., Stetler-Stevenson M. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann. N.Y. Acad. Sci. 1999, 878:522-523.
54. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708-1715.
55. Li Y.Y., Feldman A.M., Sun Y., McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98:1728-1734.
56. Fernandez C.A., Butterfield C., Jackson G., Moses M.A. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J. Biol. Chem. 2003, 278:40989-40995.
57. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal 2008, 1:re6.
58. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
59. Degryse B., Neels J.G., Czekay R.P., Aertgeerts K., Kamikubo Y., Loskutoff D.J. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem. 2004, 279:22595-22604.
60. Schroen B., Heymans S., Sharma U., Blankesteijn W.M., Pokharel S., Cleutjens J.P., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 2004, 95:515-522.
61. Chatila K., Ren G., Xia Y., Huebener P., Bujak M., Frangogiannis N.G. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc. Hematol. Agents Med. Chem. 2007, 5:21-27.
62. Angoulvant D., Fazel S., Weisel R.D., Lai T.Y., Fedak P.W., Chen L., et al. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J. Thorac. Cardiovasc. Surg. 2009, 137:471-480.